Compare Merck & Co., Inc. (MRK) vs S&P Global Inc (SPGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs S&P Global Inc — how do they compare? Merck & Co., Inc. trades at $130.93 (market cap $321.77B), while S&P Global Inc trades at $410.01 (market cap $120.48B). The key difference: Merck & Co., Inc. is far larger — about 2.7× S&P Global Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.
| MRK | SPGI | |
|---|---|---|
Market Cap | $321.77B | $120.48B |
Sector | Health | Financials |
52-Week High | $131.84 | $534.79 |
52-Week Low | $77.60 | $370.42 |
Enterprise Value | $368.53B | $131.97B |
Dividend Yield | 2.61% | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.
The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.
S&P Global (SPGI) trades at $410.94, up 0.67% on the day, with a bearish technical signal despite strong fundamentals. Revenue grew to $15.34B in 2025, with a net income margin of 30.54%, while analyst consensus remains overwhelmingly bullish with a $523.20 price target. Recent news highlights AI integration with Microsoft and strong Q2 2026 earnings beats.
The outlook is positive given robust profitability and strategic expansions, but risks include technical weakness and debt levels. Upside potential exists if the stock rebounds toward analyst targets, though investors should monitor execution against high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →
